Anat Ashkenazi

Career

1. 2024 – now
   Alphabet Inc. and Google LLCsrc
   Senior Vice President, Chief Financial Officer
   Announced 2024-06-05 and effective 2024-07-31. She succeeded Ruth Porat, who is now President & Chief Investment Officer
2. 2021 – 2024
   Eli Lilly and Companysrc
   Chief Financial Officer (elected SVP & CFO 2021-02-09; EVP & CFO by 2023)
   Resigned effective July 2024 for a role outside the pharmaceutical industry (LLY-8K-2024)
3. 2016 – 2021
   Eli Lilly and Companysrc
   Senior Vice President, Controller and CFO of Lilly Research Laboratories
   Oversaw the CFOs of the commercial businesses (BioMedicine, Diabetes, Oncology, International), R&D, manufacturing and quality, G&A, and accounting and financial reporting; also led corporate strategic planning and the business transformation office (LLY-8K-2021)
4. 2001 – 2016
   Eli Lilly and Companysrc
   Finance, strategy and Six Sigma roles: CFO of Lilly Oncology; VP Finance and CFO of Lilly Diabetes and of Global Manufacturing & Quality
   Dates of the individual divisional CFO roles not stated

Undated in the sources

• Ma'alot Standard & Poor's; Bank Hapoalim (Israel)src, Financial services

Not located: Dates of the pre-2016 Lilly divisional roles and of the pre-2001 Israeli roles are not stated in any source searched

Achievements

• Spent 23 years at Eli Lilly (2001-2024), rising to EVP & CFO from February 2021 to July 2024src
• As CFO of Lilly Research Laboratories (2016-2021) she oversaw the divisional CFOs and led corporate strategic planning and the business transformation officesrc
• Hired from outside the tech industry as Alphabet's CFO, succeeding Ruth Porat in July 2024src
• Alphabet GAAP net income rose from $100.1bn (FY2024) to $132.2bn (FY2025), her first full year as CFOsrc

Education

• The Hebrew University, BA Economics and business administrationsrc
• Tel Aviv University, MBAsrc

Background

• Family The 2026 proxy states there are no family relationships among any directors or executive officerssrc
• Other Lilly promoted her to CFO in February 2021 when her predecessor left after an investigation into inappropriate personal communications. Lilly said his conduct did not concern financial controls or statementssrc
• Other Lilly's June 2024 notice said she resigned to pursue an opportunity outside the pharmaceutical industry and would serve at full capacity through July 2024src
• Other Her Alphabet offer paid a one-time $9.9m cash sign-on bonus and a $13.1m sign-on GSU grant to replace Lilly pay she forfeited. It also set a $1.0m salary and a discretionary bonus of up to 200% of salary, which was later discontinuedsrc
• Other Early career in Israeli financial services at Ma'alot Standard & Poor's and Bank Hapoalim before joining Lilly in 2001src